drugset / Trial / NCT06440746
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
Phase 2/3
Recruiting
138 enrolled
R-Pharm International, LLC
Data Management 365 · collabExacte Labs LLC · collabKeystat, LLC · collabR-Pharm · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).
Timeline
- Start
- 2023-08-23
- Primary completion
- 2027-04-09
- Completion
- 2028-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olokizumab | Monoclonal antibody | 64 mg | Subcutaneous |